June 14, 2026
Aimee joined Breakingviews in 2017 and writes about pharmaceuticals, consumer goods groups, retail and insurance. She is also co-host of the Breakingviews podcast The Viewsroom.
Eli Lilly and Novo Nordisk dominate the weight-loss market. Yet Pfizer, Roche and others are scooping up new drugs in a bid to grab a slice of a $130 billion revenue opportunity. The potential to improve on current treatments means today’s leaders will have to share the feast.
